RapaLink-1 ide hemihydrate Smiles: C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@@H](C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)C2=C1C=CC=C2O)N(C)C

Smiles: C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@@H](C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)C2=C1C=CC=C2O)N(C)C

MEISi-2 down-regulates MEIS target gene expression

Formula: C57H62F2N10O10S2

InChi: InChI=1S/C28H31N7O2/c1-5-13-34-25(36)20-15-29-26(32-24(20)35(34)23-8-6-7-22(31-23)27(2

low intrinsic microsome clearance

RapaLink-1 ide hemihydrate Smiles: C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@@H](C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)C2=C1C=CC=C2O)N(C)CRapaLink 1, the third generation bivalent mTOR inhibitor, combines Rapamycin (HY 10219) with MLN0128 (HY 13328, a second generation mTOR kinase inhibitor) by an inert chemical linker. RapaLink 1 shows better efficacy than Rapamycin or mTOR kinase inhibitors (TORKi), potently blocking cancer derived, activating mutants of mTOR. RapaLink 1 can cross the blood brain barrier. RapaLink 1 binding to FKBP12 results in targeted and durable inhibition of